Get 50% OFF This Summer!

Advertisement
logo

Lyka Labs

LYKALABS
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Lyka Labs Share price and Fundamental Analysis

View All Details
View All Details
Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company.
Company Incorporation1976
ChairmanKUNAL NARENDRA GANDHI
Head QuartersMumbai
Previous NameNA

Key Metrics

Market Cap (Cr)
382.24
PE Ratio
93.13
Industry P/E
35.07
PEG Ratio
-0.45
ROE
3.23%
ROCE
7.2%
ROA
2.45%
Total Debt (Cr)
35.16
Debt to Equity
0.36
Dividend Yield
0%
EPS
1.15
Book Value & P/B
27.71 x 3.86
Face Value
10
Outstanding Shares(Cr)
3.57
Current Ratio
2.08
EV to Sales
3.13

Stock Returns

1 Week-3.47%
1 Month+2.74%
6 Months-26.16%
1 Year-6.32%
3 Years-16.89%
5 Years+593.88%

CAGR

1 Year CAGR

Revenue Growth

+19.47%

Net Profit Growth

-80.08%

Operating Profit Growth

+30.45%

Dividend Growth

N/A

Stock Returns CAGR

-6.34%
no_data

No Stocks

Smart Score

1.7
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 58.16%

FIIs : 0.23%

DIIs : 0.67%

Public : 40.94%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
Promoter Shareholding Increased by 0.06% to 58.16% in March 2025 Qtr
FII Shareholding Increased by 0.08% to 0.23% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Lyka Labs Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Lyka Labs Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company.

The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking.

A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance.

During 1997-98, the company's administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system by SGS Yarsley International Certification Services Limited, UK.

The production carried out at Bombay has been shifted to Tarapur and Ankleshwar in the year 1999-2000, inorder to achieve economies of scale and better compliance. The company has assigned Trade Marks and transferred technical, marketing know-how and allied rights pertaining to some of its products.

The Company's factory at Tarapur, re-commissioned production in March, 2013. It launched Glutathione Injection, a 'First Time in India' formulation during 2012-13. It commissioned the production at Ankleshwar factory.

During Financial Year 2013-14, the Company had floated a Wholly Owned Subsidiary Company namely Lyka Healthcare Limited to focus, develop and expand Domestic Marketing of Ethical Products. Its another subsidiary, Lyka Exports Limited reorganized its activities and resultant, it sold the Animal Healthcare Business in 2014. The subsidiaries, Lyka Healthcare Limited and Lyka Exports Limited merged with the Company which became effective from April 01, 2016.

During the year 2021-22, IPCA together with persons acting in concert acquired 26.70% shares of the Company through Public Offer consisting a total shareholding of 27.76% of the Paid-up Equity Capital of the Company and resultant to acquisition in stake, became the Joint Promoters of Company.

Lyka Labs Share Price

Lyka Labs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Lyka Labs Market Cap

Market capitalization of Lyka Labs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Lyka Labs is valued compared to its competitors.

Lyka Labs PE Ratio

Lyka Labs PE ratio helps investors understand what is the market value of each stock compared to Lyka Labs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Lyka Labs PEG Ratio

The PEG ratio of Lyka Labs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Lyka Labs ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Lyka Labs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Lyka Labs ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Lyka Labs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Lyka Labs Total Debt

Total debt of Lyka Labs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Lyka Labs Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Lyka Labs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Lyka Labs CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Lyka Labs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Lyka Labs Technical Analysis

Technical analysis of Lyka Labs helps investors get an insight into when they can enter or exit the stock. Key components of Lyka Labs Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Lyka Labs shares often struggle to rise above due to selling pressure.

Lyka Labs Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Lyka Labs ’s financial health and profitability.

Lyka Labs Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Lyka Labs Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Lyka Labs Financials

The financials of Lyka Labs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Lyka Labs Profit and Loss Statements

The profit and loss statement of Lyka Labs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Lyka Labs .

Lyka Labs Balance Sheet

The balance sheet presents a snapshot of Lyka Labs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Lyka Labs Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App